Cargando…

Mechanism of CD38 via NAD(+) in the Development of Non-alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally, and it can proceed to cirrhosis and hepatocellular carcinoma, as well as cardiovascular disease, chronic renal disease, and other complications, resulting in a massive economic burden. At the moment, nicotin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Min, Wang, Shuo, Pei, Zuowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925988/ https://www.ncbi.nlm.nih.gov/pubmed/36794157 http://dx.doi.org/10.7150/ijms.81381

Ejemplares similares

CD38 regulates ovarian function and fecundity via NAD(+) metabolism
por: Perrone, Rosalba, et al.
Publicado: (2023)

OXPHOS-Mediated Induction of NAD(+) Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease
por: Akie, Thomas E., et al.
Publicado: (2015)

CD38 is methylated in prostate cancer and regulates extracellular NAD(+)
por: Mottahedeh, Jack, et al.
Publicado: (2018)

CD38-NAD(+)-Sirt1 axis in T cell immunotherapy
por: Chatterjee, Shilpak, et al.
Publicado: (2019)

Silibinin Restores NAD(+) Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver
por: Salomone, Federico, et al.
Publicado: (2017)

NAD(+): A key metabolic regulator with great therapeutic potential for myocardial infarction via Sirtuins family
por: Yao, Wei, et al.
Publicado: (2023)

Targeting CD38-dependent NAD(+) metabolism to mitigate multiple organ fibrosis
por: Shi, Bo, et al.
Publicado: (2020)

Flavonoid Apigenin Is an Inhibitor of the NAD(+)ase CD38: Implications for Cellular NAD(+) Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome
por: Escande, Carlos, et al.
Publicado: (2013)

NAD(+) exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension
por: Qiu, Yumin, et al.
Publicado: (2023)

Macrophage Immunometabolism and Inflammaging: Roles of Mitochondrial Dysfunction, Cellular Senescence, CD38, and NAD
por: Yarbro, Johnathan R., et al.
Publicado: (2020)

Serum interleukin-38 levels correlated with insulin resistance, liver injury and lipids in non-alcoholic fatty liver disease
por: Cao, Jun, et al.
Publicado: (2022)

The new insight into extracellular NAD(+) degradation‐the contribution of CD38 and CD73 in calcific aortic valve disease
por: Jablonska, Patrycja, et al.
Publicado: (2021)

NNMT activation can contribute to the development of fatty liver disease by modulating the NAD(+) metabolism
por: Komatsu, Motoaki, et al.
Publicado: (2018)

Design, Synthesis and SAR Studies of NAD Analogues as Potent Inhibitors towards CD38 NADase
por: Wang, Shengjun, et al.
Publicado: (2014)

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD(+)-Lowering Agents
por: Becherini, Pamela, et al.
Publicado: (2023)

Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease
por: Sun, Chao, et al.
Publicado: (2015)

Remission of social behavior impairment by oral administration of a precursor of NAD in CD157, but not in CD38, knockout mice
por: Gerasimenko, Maria, et al.
Publicado: (2023)

Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
por: Gupta, Haripriya, et al.
Publicado: (2022)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Molecular mechanism of alcoholic fatty liver
por: Rasineni, Karuna, et al.
Publicado: (2012)

Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis
por: Lin, Pei, et al.
Publicado: (2015)

Macrophages and the development and progression of non-alcoholic fatty liver disease
por: Alabdulaali, Bader, et al.
Publicado: (2023)

CD38 ecto-enzyme in immune cells is induced during aging regulating NAD(+) and NMN levels
por: Chini, Claudia C.S., et al.
Publicado: (2020)

MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36
por: Wang, Xin, et al.
Publicado: (2020)

NAD(+)-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin
por: Li, Dong-Jie, et al.
Publicado: (2021)

Insights into the Mechanism of Bovine CD38/NAD+Glycohydrolase from the X-Ray Structures of Its Michaelis Complex and Covalently-Trapped Intermediates
por: Egea, Pascal F., et al.
Publicado: (2012)

Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis
por: Zhu, Weifeng, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice
por: Sun, Hang, et al.
Publicado: (2016)

Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease
por: Zhao, Man, et al.
Publicado: (2022)

Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
por: Kawano, Yuki, et al.
Publicado: (2013)

Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease
por: Garbuzenko, Dmitry Victorovich
Publicado: (2022)

Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
por: Petagine, Lucy, et al.
Publicado: (2023)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver
por: Yao, Jiayin, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_766sk8flfcf0d7cr9kgj5ni134